Blog
Read our latest blog posts on biotech, AI, and funding rare disease research.
The Great Disruption: how Chinese assets will reshape drug development
Chinese biopharma companies are at an inflection point, with rapidly advancing in science, know-how, + talent. Chinese assets are poised
5 insights from JPM 2025
Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet
AI for biopharma business development: finding the right assets faster
By combining human expertise with AI-powered analysis, we’re helping biopharma companies make faster, more informed business development decisions.
3 key ways AI-powered analysis supports drug development
Artificial intelligence-powered pipeline analysis is emerging as a tool that can help teams make better, faster drug development decisions.
5 guardrails you MUST implement when using AI in biopharma
Implementing guardrails for artificial intelligence (AI) in the biopharmaceutical industry is crucial for ensuring effective, safe, and compliant use of
Biotech Limited Partners: learnings from investing in biotech venture capital funds
Limited Partners (LPs) are at the heart of the biotech funding ecosystem—these crucial players ignite the funding flywheel that drives
